Biocon Ltd. — Capital/Financing Update 2026

Jan 15, 2026

==> picture [132 x 53] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com

BIO/SECL/EA/2025-26/163

January 14, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Dear Sir/ Madam,

Subject: Press Release

Please find enclosed the press release titled “ Biocon Limited Concludes Rs 4,150 Crore (~USD 460 million) Equity Fundraise through a Qualified Institutions Placement (QIP)”.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

RAJESH Digitally signed by RAJESH UMAKANT UMAKANT SHANOY SHANOY Date: 2026.01.14 23:56:01 +05'30'

---

Rajesh U. Shanoy Company Secretary and Compliance Officer M. No.: ACS 16328

Encl: Press Release

==> picture [80 x 30] intentionally omitted <==

==> picture [132 x 30] intentionally omitted <==

PRESS RELEASE

Biocon Limited Concludes Rs 4,150 Crore (~USD 460[1] million) Equity Fundraise through a Qualified Institutions Placement (QIP)

Bengaluru, Karnataka, India: January 14, 2026:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceutical company, today announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per Equity Share (including a premium of Rs 363.35 per Equity Share).

The QIP, which opened on January 12, 2026, and closed on January 14, 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon’s growth prospects.

The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris’ stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.

This integration marks a pivotal step in Biocon’s journey to lead in the therapeutic areas of diabetes, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP-1s). The integration process is expected to be completed no later than March 31, 2026.

Key Transaction Highlights:

• QIP saw healthy interest from all pools of capital across Domestic Mutual Funds (“MFs”), Domestic Insurance Companies, and Foreign Institutional Investors (“FIIs”) – highlighting investor’s confidence in Biocon’s differentiated business model and growth potential of the combined business.

• Witnessed interest from 39 investors and allocations to all 39 investors.

• Robust participation from leading financial institutions including SBI Mutual Fund, ICICI Prudential Mutual Fund, Mirae Asset Mutual Fund, Birla Mutual Fund, HDFC Life Insurance, ICICI Prudential Life Insurance, JPMorgan Asset Management, among others.

The net proceeds from the QIP will be utilized for:

• Payment of cash consideration to Mylan Inc. (Viatris) for acquisition of shares of Biocon Biologics Limited, including repayment of debt availed in this regard.

• Re-payment of debt availed, for the acquisition of compulsory convertible debentures (CCDs) of Biocon Biologics Limited, held by Edelweiss.

• General corporate purposes.

The Company received shareholders’ approval for the fundraise at the Extra-Ordinary General Meeting held on December 31, 2025.

Book Running Lead Managers and Legal Counsels: Kotak Mahindra Capital Company Limited, HSBC Securities and Capital Markets (India) Private Limited, J.P. Morgan India Private Limited and Morgan Stanley India Company Private Limited acted as Book Running Lead Managers to the QIP. Shardul

1 1 USD – Rs 90.165

1

==> picture [80 x 30] intentionally omitted <==

==> picture [132 x 30] intentionally omitted <==

Amarchand Mangaldas & Co. was the Legal Counsel to the Company while Linklaters Singapore Pte. Ltd. and JSA Advocates & Solicitors were the Legal Counsels to the Book Running Lead Managers.

About Biocon Limited

Biocon Limited , publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceutical company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com Follow-us on X ( formerly Twitter ) @bioconlimited and LinkedIn : @BioconLimited for company updates. For FY25 Integrated Annual Report of Biocon click here

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing on its ‘lab to market’ capabilities to serve over 6.3 million patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. Biocon Biologics has commercialized 10 biosimilars from its portfolio which are addressing the patients’ needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20+ biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other noncommunicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on X (formerly Twitter) : @BioconBiologics and LinkedIn : Biocon Biologics for company updates.

FOR MORE INFORMATION
For Media Rumman Ahmed Senior Director, Biocon Biologics +91 98451 04173 rumman.ahmed@biocon.com Lance Longwell Public Relations Lead – Advanced Markets, Biocon Biologics +1 857 270 4391 lance.longwell@biocon.com	For Investors Prashant Nair Head – Investor Relations, Biocon Biologics +91 98200 95476 Prashant.nair@biocon.com

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

2